Oncomatryx Biopharma
Biopharmaceutical company focused on the tumor microenvironment, and developeds precision drugs and diagnostic devices.
Launch date
Employees
Market cap
-
Enterprise valuation
€60—90m (Dealroom.co estimates Apr 2022.)
Company register number B95586780
Derio Basque Country (HQ)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | 4.4m | 1.2m | 1.3m |
% growth | 1 % | (73 %) | 10 % | 10943 % | 1124 % | (73 %) | 5 % |
EBITDA | (<1m) | (<1m) | (<1m) | (<1m) | 3.1m | (1.1m) | - |
% EBITDA margin | (6477 %) | (23613 %) | (21518 %) | (98 %) | 70 % | (93 %) | - |
Profit | (1.5m) | (1.9m) | (1.7m) | (2.2m) | <1m | (2.9m) | - |
% profit margin | (13444 %) | (63420 %) | (52765 %) | (604 %) | 14 % | (246 %) | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
€60.0k | Grant | ||
N/A | Support Program | ||
€39.5k | Grant | ||
€35.1k | Grant | ||
* | €4.5m | Early VC | |
€60.0k | Grant | ||
€23.7k | Grant | ||
€27.7k | Grant | ||
* | $9.0m | Early VC | |
€28.4k | Grant | ||
* | €15.0m | Series A | |
Total Funding | €28.0m |
Recent News about Oncomatryx Biopharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Oncomatryx Biopharma
EditACQUISITION by Oncomatryx Biopharma May 2023